Glioblastoma

Oncology 0 original drugs

Novel Drugs

Reformulations

Drug Targets

Oncology indication. Glioblastoma has 0 FDA-approved novel treatments, with 350 active industry clinical trials across 4 drug targets. Explore market leaders, treatments by mechanism, the clinical pipeline, and drug targets below.

Phase 3 Readouts Pro

7 active Phase 3 trials with confidence-graded completion dates.

Full calendar →

Q4 2026

Bevacizumab

NaviFUS Corporation

Estimated · fresh NCT06496971

Q4 2026

TVI-Brain-1

TVAX Biomedical

Estimated · aging NCT05685004

Q3 2027

—

Telix Pharmaceuticals (Innovations) Pty Limited

Estimated · fresh NCT07100730

Unlock 4 more readouts with confidence-graded estimates

Upgrade to Pro

Anchored on CT.gov primary completion date. Topline announcements typically precede this by 3–9 months. Confidence labels combine date type (ACTUAL/ESTIMATED) with last-update freshness.

Glioblastoma Treatments by Mechanism

Top 10 mechanisms across 31 industry trials with a known mechanism of action.

See full pipeline →

Alkylating Drug

10 trials 2 active 9 sponsors

Vascular Endothelial Growth Factor Inhibitor

7 trials 2 active 5 sponsors

Platinum-based Drug

4 trials 1 active 2 sponsors

Contrast Agent for Ultrasound Imaging

1 trials 1 active 1 sponsor

Hypoxia-inducible Factor Inhibitor

1 trials 1 active 1 sponsor

Endoglycosidase

3 trials 3 sponsors

Nuclear Export Inhibitor

2 trials 1 sponsor

Kinase Inhibitor

1 trials 1 sponsor

ABL kinase/BCR-ABL/EPHA2/FYN/LCK/PDGFRβ/SRC/YES/c-KIT

1 trials 1 sponsor

DNA

1 trials 1 sponsor

MoA derived from FDA pharmClassEpc when intervention matches an approved drug. Codenamed clinical-stage assets without an approved counterpart show "—" and aren't grouped here — they're still in the phase tables below.

Glioblastoma Clinical Pipeline by Phase

284 industry-sponsored trials across 179 sponsors

View full landscape →

Showing 5 of 5 trials

Sponsor	Asset	MoA	Status	Primary Completion	NCT
Novartis	dabrafenib	—	RECRUITING	2026-11-05	NCT03975829
GT Medical Technologies, Inc.	—	—	ACTIVE NOT RECRUITING	2027-12-01	NCT05342883
Merck	Temozolomide	Alkylating Drug [EPC]	COMPLETED	2011-09-28	NCT00686725
NovoCure Ltd.	—	—	TERMINATED	2018-01	NCT01756729
GT Medical Technologies, Inc.	—	—	WITHDRAWN	2026-06	NCT05900908

Showing 30 of 30 trials

Sponsor	Asset	MoA	Status	Primary Completion	NCT
NaviFUS Corporation	Bevacizumab	Vascular Endothelial Growth Factor Inhibitor [EPC]	RECRUITING	2026-12-31	NCT06496971
Telix Pharmaceuticals (Innovations) Pty Limited	—	—	RECRUITING	2027-07	NCT07100730
CarThera	Carboplatin	Platinum-based Drug [EPC]	RECRUITING	2028-01-28	NCT05902169
NovoCure GmbH	Temozolomide	Alkylating Drug [EPC]	RECRUITING	2029-04	NCT06556563
GT Medical Technologies, Inc.	Temozolomide	Alkylating Drug [EPC]	RECRUITING	2031-12	NCT07195591
TVAX Biomedical	TVI-Brain-1	—	ACTIVE NOT RECRUITING	2026-12	NCT05685004
Laminar Pharmaceuticals	LAM561	—	ACTIVE NOT RECRUITING	2026-01-15	NCT04250922
Ascletis Pharmaceuticals Co., Ltd.	ASC40 tablets	—	ACTIVE NOT RECRUITING	2025-06	NCT05118776
Beijing Pearl Biotechnology Limited Liability Company	PLB1001	—	ACTIVE NOT RECRUITING	2023-04-01	NCT06105619
Aivita Biomedical, Inc.	AV-GBM-1	—	NOT YET RECRUITING	2028-03	NCT05100641
Everfront Biotech Co., Ltd.	Cerebraca wafer	—	NOT YET RECRUITING	2028-12-01	NCT07349693
Denovo Biopharma LLC	Enzastaurin Hydrochloride	—	COMPLETED	2024-02-29	NCT03776071
Cordgenics, LLC	Chemotherapy	—	COMPLETED	2022-06-16	NCT03632135
AbbVie	Temozolomide	Alkylating Drug [EPC]	COMPLETED	2022-04-04	NCT02573324
Sumitomo Pharma America, Inc.	DSP-7888 Dosing Emulsion	—	COMPLETED	2021-08-30	NCT03149003
Bristol-Myers Squibb	Nivolumab	Endoglycosidase [EPC]	COMPLETED	2019-06-17	NCT02017717
Vascular Biogenics Ltd. operating as VBL Therapeutics	VB-111 + bevacizumab	—	COMPLETED	2017-11-03	NCT02511405
NovoCure Ltd.	Temozolomide	Alkylating Drug [EPC]	COMPLETED	2016-12	NCT00916409
Celldex Therapeutics	Rindopepimut (CDX-110) with GM-CSF	—	COMPLETED	2016-11	NCT01480479
Roche	Bevacizumab	Vascular Endothelial Growth Factor Inhibitor [EPC]	COMPLETED	2013-02-28	NCT00943826
EMD Serono	Cilengitide	—	COMPLETED	2012-11	NCT00689221
GC Cell Corporation	Activated T lymphocyte(Immuncell-LC)	—	COMPLETED	2012-10	NCT00807027
AstraZeneca	Cediranib	—	COMPLETED	2010-04	NCT00777153
Diffusion Pharmaceuticals Inc	Trans Sodium Crocetinate plus SOC	—	TERMINATED	2020-11-06	NCT03393000
AbbVie	Steroid eye drops	—	TERMINATED	2019-09-05	NCT03419403
DelMar Pharmaceuticals, Inc.	VAL-083, Dianhydrogalactitol	—	TERMINATED	2019-05-31	NCT03149575
Tocagen Inc.	Toca 511	—	TERMINATED	2019-05-31	NCT02414165
Bradmer Pharmaceuticals Inc.	Neuradiab + Radiotherapy + Temozolomide	—	TERMINATED	2013-08	NCT00615186
Isarna Therapeutics GmbH	trabedersen	—	TERMINATED	2012-02	NCT00761280
Precision Life Sciences Group	ICT-107	—	SUSPENDED	2025-12	NCT02546102

Showing 100 of 152 trials (top 100 by completion date — export for full list)

Sponsor	Asset	MoA	Status	Primary Completion	NCT
JenKem Technology Co., Ltd.	JK-1201I	—	RECRUITING	2026-08-16	NCT06595186
Sichuan Baili Pharmaceutical Co., Ltd.	BL-B01D1 for Injection	—	RECRUITING	2026-10	NCT06598787
Philogen S.p.A.	Onfekafusp alfa	—	RECRUITING	2026-10	NCT04443010
Myosin Therapeutics Inc.	MT-125	—	RECRUITING	2026-10-31	NCT07185880
Ever Supreme Bio Technology Co., Ltd.	autologous dendritic cells	—	RECRUITING	2026-12-30	NCT04115761
Neonc Technologies, Inc.	NEO212 Oral Capsule	—	RECRUITING	2027-02-28	NCT06047379
Tango Therapeutics, Inc.	TNG456	—	RECRUITING	2027-03-31	NCT06810544
Filamon LTD	A novel hGIIA-Vimentin Inhibitor	—	RECRUITING	2027-10-26	NCT06926075
Alpheus Medical, Inc.	—	—	RECRUITING	2027-12	NCT07225621
NaviFUS Corporation	Lumason	Contrast Agent for Ultrasound Imaging [EPC]	RECRUITING	2027-12-31	NCT06329570
BioNTech SE	Pumitamig	—	RECRUITING	2028-01	NCT07297212
Tasly Pharmaceutical Group Co., Ltd	P134 cell injection	—	RECRUITING	2028-02-29	NCT07318818
Debiopharm International SA	Debio 0123	—	RECRUITING	2028-09	NCT05765812
Black Diamond Therapeutics, Inc.	silevertinib in combination with temozolomide	—	RECRUITING	2028-11	NCT07326566
Guangzhou Virotech Pharmaceutical Co., Ltd.	VRT106	—	RECRUITING	2028-12-31	NCT07093814
ImmunityBio, Inc.	Bevacizumab	Vascular Endothelial Growth Factor Inhibitor [EPC]	RECRUITING	2029-12-31	NCT06061809
Trogenix ltd	TGX-007	—	RECRUITING	2030-03	NCT07346144
Diakonos Oncology Corporation	DOC1021	—	RECRUITING	2030-03	NCT06805305
Jecho Biopharmaceuticals Co., Ltd.	JL15003Injection	—	RECRUITING	2030-04	NCT07501559
Neonc Technologies, Inc.	Perillyl alcohol	—	RECRUITING	2026-03-30	NCT02704858
Apollomics Inc.	APL-101 Oral Capsules	—	RECRUITING	2026-03-30	NCT03175224
SignPath Pharma, Inc.	Treatment Period 1	—	RECRUITING	2026-02	NCT05768919
Aveta Biomics, Inc.	APG-157	—	RECRUITING	2025-12-31	NCT06011109
Marzieh Ebrahimi	NK cell therapy	—	RECRUITING	2025-11-25	NCT06687681
Genenta Science	Temferon	—	ACTIVE NOT RECRUITING	2026-06-30	NCT03866109
NuvOx LLC	NanO2TM	—	ACTIVE NOT RECRUITING	2026-06-30	NCT03862430
Lantern Pharma Inc.	LP-184	—	ACTIVE NOT RECRUITING	2026-07-28	NCT05933265
BPGbio	BPM31510	—	ACTIVE NOT RECRUITING	2026-08-25	NCT04752813
Cantex Pharmaceuticals	Azeliragon	—	ACTIVE NOT RECRUITING	2026-09-30	NCT05986851
GSK	Cobolimab	—	ACTIVE NOT RECRUITING	2026-10-13	NCT06521567
Sapience Therapeutics	ST101	—	ACTIVE NOT RECRUITING	2026-12	NCT04478279
Inovio Pharmaceuticals	INO-5401	—	ACTIVE NOT RECRUITING	2026-12-31	NCT03491683
Polaris Group	ADI-PEG 20	—	ACTIVE NOT RECRUITING	2027-02-28	NCT04587830
Nerviano Medical Sciences	NMS-03305293	—	ACTIVE NOT RECRUITING	2027-05-30	NCT04910022
TME Pharma AG	Olaptesed pegol	—	ACTIVE NOT RECRUITING	2028-12	NCT04121455
Philogen S.p.A.	L19TNF	—	ACTIVE NOT RECRUITING	2026-06	NCT06336291
Imvax	SOC: Temozolomide	—	ACTIVE NOT RECRUITING	2026-06	NCT04485949
CNS Pharmaceuticals, Inc.	Berubicin	—	ACTIVE NOT RECRUITING	2026-04-27	NCT04762069
Hemerion Therapeutics	—	—	ACTIVE NOT RECRUITING	2026-03-06	NCT05736406
Epitopoietic Research Corporation	ERC1671	—	ACTIVE NOT RECRUITING	2026-03	NCT01903330
In8bio Inc.	Autologous genetically modified gamma-delta T cells	—	ACTIVE NOT RECRUITING	2025-12	NCT05664243
NGM Biopharmaceuticals, Inc	NGM707	—	ACTIVE NOT RECRUITING	2025-02	NCT04913337
Acerta Pharma BV	ACP-196	—	ACTIVE NOT RECRUITING	2020-06-26	NCT02586857
Myosin Therapeutics Inc.	MT-125	—	NOT YET RECRUITING	2027-03	NCT07604285
Starlight Therapeutics Inc.	STAR-001 (LP-184) will be administered via IV infusion over 30 (± 5) minutes on Day 1 and Day 8 of each 21-day cycle.	—	NOT YET RECRUITING	2027-05-01	NCT07431216
Sichuan Honghe Biotechnology Co., Ltd.	KH617	—	NOT YET RECRUITING	2027-09	NCT07138001
T-MAXIMUM Pharmaceutical Inc	Intracerebroventricular injection of MT027 UCAR-T Cell targeting B7H3	—	NOT YET RECRUITING	2028-12-13	NCT07386002
ZSky Biotech Inc	Personalized Dendritic Cell Vaccine ZSNeo-DC1.1	—	NOT YET RECRUITING	2028-12-24	NCT07365280
CRISM Therapeutics LTD	irinotecan-ChemoSeed implementation into the resection cavity after surgical resection of GBM	—	NOT YET RECRUITING	2029-05	NCT07356973
NeuGATE Theranostics	Temozolomide	Alkylating Drug [EPC]	NOT YET RECRUITING	2030-07-30	NCT04373785
Cantex Pharmaceuticals	Azeliragon 5 mg	—	COMPLETED	2026-04-30	NCT05635734
PharmaMar	Lurbinectedin	Alkylating Drug [EPC]	COMPLETED	2025-07-01	NCT02611024
Kintara Therapeutics, Inc.	VAL-083, Dianhydrogalactitol	—	COMPLETED	2024-12-30	NCT02717962
Merck	Pembrolizumab	Endoglycosidase [EPC]	COMPLETED	2024-10-28	NCT03797326
Istari Oncology, Inc.	lerapolturev	—	COMPLETED	2024-06-05	NCT04479241
Oblato, Inc.	OKN-007	—	COMPLETED	2024-05-08	NCT04388475
Enterome	Multiple dose of EO2401	—	COMPLETED	2024-03-04	NCT04116658
InSightec	Carboplatin	Platinum-based Drug [EPC]	COMPLETED	2023-11-30	NCT04417088
InSightec	Carboplatin	Platinum-based Drug [EPC]	COMPLETED	2023-11-30	NCT04440358
BioMimetix JV, LLC	BMX-001	—	COMPLETED	2023-08-17	NCT02655601
MediciNova	MN-166	—	COMPLETED	2023-08-07	NCT03782415
NovoCure GmbH	—	—	COMPLETED	2023-06-20	NCT04492163
Kazia Therapeutics Limited	Paxalisib (GDC-0084)	—	COMPLETED	2023-03-30	NCT03522298
Aadi Bioscience, Inc.	nab-sirolimus	—	COMPLETED	2022-08-26	NCT03463265
Telix Pharmaceuticals (Innovations) Pty Limited	—	—	COMPLETED	2022-07-31	NCT03849105
Gan and Lee Pharmaceuticals, USA	GLR2007	—	COMPLETED	2022-07-29	NCT04444427
Kintara Therapeutics, Inc.	VAL-083 (Dianhydrogalactitol)	—	COMPLETED	2021-11-22	NCT03050736
Novartis	Dabrafenib	—	COMPLETED	2021-08-23	NCT02684058
CarThera	Carboplatin	Platinum-based Drug [EPC]	COMPLETED	2021-06-23	NCT03744026
Bristol-Myers Squibb	MRZ	—	COMPLETED	2021-06-02	NCT02330562
Forma Therapeutics, Inc.	FT-2102	—	COMPLETED	2021-05-24	NCT03684811
DNAtrix, Inc.	DNX-2401	—	COMPLETED	2021-03-17	NCT02798406
AbbVie	Temozolomide	Alkylating Drug [EPC]	COMPLETED	2020-08-27	NCT02590263
Arog Pharmaceuticals, Inc.	crenolanib	—	COMPLETED	2020-07	NCT02626364
Incyte Corporation	Nivolumab	Endoglycosidase [EPC]	COMPLETED	2020-06-16	NCT02327078
Kadmon Corporation, LLC	Tesevatinib	—	COMPLETED	2020-04-30	NCT02844439
Sumitomo Pharma Co., Ltd.	DSP-7888	—	COMPLETED	2020-01	NCT02750891
CytoVac A/S	ALECSAT	—	COMPLETED	2019-11-14	NCT02799238
Medicenna Therapeutics, Inc.	MDNA55	—	COMPLETED	2019-09-12	NCT02858895
AbbVie	Depatuxizumab mafodotin	—	COMPLETED	2019-06-24	NCT02343406
Gilead	Sacituzumab Govitecan-hziy (SG)	—	COMPLETED	2019-03-01	NCT01631552
Celldex Therapeutics	Combination of varlilumab and nivolumab	—	COMPLETED	2018-12-12	NCT02335918
Sumitomo Pharma America, Inc.	BBI608	—	COMPLETED	2018-10-09	NCT02315534
Novartis	BGJ398	—	COMPLETED	2018-10-03	NCT01975701
Cantex Pharmaceuticals	Disulfiram/Copper	—	COMPLETED	2018-07-10	NCT03034135
NewLink Genetics Corporation	Indoximod	—	COMPLETED	2018-04-18	NCT02052648
Daiichi Sankyo	PLX3397	—	COMPLETED	2017-11-03	NCT01790503
Stemline Therapeutics, Inc.	SL-701; poly-ICLC (polyinosinic-polycytidylic acid stabilized with polylysine and carboxymethyl cellulose)	—	COMPLETED	2017-09-01	NCT02078648
PharmAbcine	TTAC-0001	—	COMPLETED	2017-06-02	NCT03033524
Roche	Bevacizumab	Vascular Endothelial Growth Factor Inhibitor [EPC]	COMPLETED	2017-01-13	NCT01860638
ImmunityBio, Inc.	250 mg/m2 aldoxorubicin	—	COMPLETED	2016-12	NCT02014844
GenSpera, Inc.	G-202	—	COMPLETED	2016-12	NCT02067156
Bristol-Myers Squibb	CC-223	—	COMPLETED	2016-11-15	NCT01177397
Angiochem Inc	ANG1005	—	COMPLETED	2016-02	NCT01967810
Roche	Bevacizumab	Vascular Endothelial Growth Factor Inhibitor [EPC]	COMPLETED	2016-01-21	NCT01632228
Kintara Therapeutics, Inc.	VAL-083 (Dianhydrogalactitol)	—	COMPLETED	2015-12	NCT01478178
Diffusion Pharmaceuticals Inc	Trans Sodium Crocetinate (TSC)	—	COMPLETED	2015-11	NCT01465347
Vascular Biogenics Ltd. operating as VBL Therapeutics	VB-111	—	COMPLETED	2015-07-23	NCT01260506
Sanofi	bsi-201 plus temozolomide	—	COMPLETED	2015-06	NCT00687765
Tracon Pharmaceuticals Inc.	TRC105	—	COMPLETED	2015-06	NCT01564914

Showing 97 of 97 trials

Sponsor	Asset	MoA	Status	Primary Completion	NCT
Orbus Therapeutics, Inc.	Eflornithine (Dose Level 1)	—	RECRUITING	2026-06-30	NCT05879367
Jazz Pharmaceuticals	ONC206	—	RECRUITING	2026-07	NCT04541082
Boston Scientific Corporation	—	—	RECRUITING	2026-07-31	NCT05303467
AstraZeneca	AZD1390	—	RECRUITING	2026-09-16	NCT03423628
BeyondBio Inc.	BEY1107	—	RECRUITING	2026-11-30	NCT05769660
RasCal Therapeutics, Inc.	RSC-1255 Dose Escalation	—	RECRUITING	2026-12-15	NCT04678648
Orano Med LLC	²¹²Pb-DOTAM-GRPR1	—	RECRUITING	2027-01	NCT05283330
Beijing Biotech	Dual-target CAR-NK cells	—	RECRUITING	2027-02-18	NCT07480941
Beijing Biotech	Dual-target CAR-NK cells	—	RECRUITING	2027-04-14	NCT07551336
Tetragon Biosciences Ltd	GLIX1	—	RECRUITING	2027-06	NCT07464925
Chipscreen Biosciences, Ltd.	CS231295	—	RECRUITING	2029-04	NCT06902350
Telix Pharmaceuticals (Innovations) Pty Limited	131I-IPA	—	RECRUITING	2026-06	NCT05450744
Sichuan Luzhou Buchang Biopharmaceutical Co., Ltd.	BC008-1A	—	RECRUITING	2026-06	NCT06773481
Phost'In Therapeutics	PhOx430	—	RECRUITING	2024-11-04	NCT05495295
Chimeric Therapeutics	CHM-1101 CAR-T cells	—	ACTIVE NOT RECRUITING	2026-12	NCT05627323
Novartis	[177Lu]Lu-NeoB	—	ACTIVE NOT RECRUITING	2028-11-08	NCT05739942
Immunomic Therapeutics, Inc.	ITI-1001	—	ACTIVE NOT RECRUITING	2026-03	NCT05698199
Novartis	[177Lu]Lu-DOTA-TATE	—	ACTIVE NOT RECRUITING	2025-12-03	NCT05109728
Katmai Pharmaceuticals Inc.	ERAS-801	—	ACTIVE NOT RECRUITING	2025-08-31	NCT05222802
Oblato, Inc.	Low-dose OKN-007, BID	—	ACTIVE NOT RECRUITING	2025-05-31	NCT05561374
Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)	Belzutifan	Hypoxia-inducible Factor Inhibitor [EPC]	ACTIVE NOT RECRUITING	2018-01-12	NCT02974738
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.	FZ-AD005	—	NOT YET RECRUITING	2027-12-01	NCT07455045
Crimson Biopharm Inc.	CM93	—	NOT YET RECRUITING	2029-07	NCT04933422
Beijing Tricision Biotherapeutics Inc	Survivin-loaded dendritic cell injection	—	NOT YET RECRUITING	2025-12-01	NCT06524063
Theragnostics Ltd	123I-ATT001	—	COMPLETED	2026-03-01	NCT06650605
CureVac	CV09050101 mRNA vaccine (CVGBM) 12 μg	—	COMPLETED	2026-02-02	NCT05938387
Boehringer Ingelheim	BI 907828 (Brigimadlin)	—	COMPLETED	2025-07-31	NCT05376800
Roche	RO7428731	—	COMPLETED	2025-05-14	NCT05187624
Prelude Therapeutics	PRT3645	—	COMPLETED	2024-06-26	NCT05538572
Jecho Biopharmaceuticals Co., Ltd.	JL15003 Injection	—	COMPLETED	2024-05-23	NCT07497373
Bristol-Myers Squibb	CC-122	—	COMPLETED	2023-11-21	NCT01421524
BerGenBio ASA	Bemcentinib	—	COMPLETED	2022-09-23	NCT06469138
Istari Oncology, Inc.	Polio/Rhinovirus Recombinant (PVSRIPO)	—	COMPLETED	2022-03-23	NCT03043391
Engeneic Pty Limited	EGFR(V)-EDV-Dox	—	COMPLETED	2021-08-21	NCT02766699
Bristol-Myers Squibb	CC-115	—	COMPLETED	2021-03-12	NCT01353625
Bristol-Myers Squibb	MRZ	—	COMPLETED	2021-01-25	NCT02903069
Stemgen	hrBMP4	—	COMPLETED	2020-10-16	NCT02869243
Alaunos Therapeutics	Ad-RTS-hIL-12	—	COMPLETED	2020-10-15	NCT03636477
Genexine, Inc.	GX-I7	—	COMPLETED	2020-09-25	NCT03619239
Laminar Pharmaceuticals	LAM561	—	COMPLETED	2020-07-01	NCT03867123
NewLink Genetics Corporation	Indoximod	—	COMPLETED	2019-12-12	NCT02502708
EpicentRx, Inc.	RRx-001 dose escalation with TMZ + RT	—	COMPLETED	2019-10-11	NCT02871843
Alaunos Therapeutics	Ad-RTS-hIL-12	—	COMPLETED	2019-08	NCT02026271
Incuron	CBL0137	—	COMPLETED	2019-05	NCT01905228
Alaunos Therapeutics	Ad-RTS-hIL-12	—	COMPLETED	2019-04-02	NCT03679754
CANbridge Life Sciences Ltd.	CAN008	—	COMPLETED	2018-09	NCT02853565
Sumitomo Pharma America, Inc.	DSP-7888 Dosing Emulsion	—	COMPLETED	2018-08	NCT02498665
Bristol-Myers Squibb	CC-486	—	COMPLETED	2018-06-11	NCT02223052
Immatics Biotechnologies GmbH	APVAC1 vaccine plus Poly-ICLC and GM-CSF	—	COMPLETED	2018-06	NCT02149225
DNAtrix, Inc.	Single intratumoral injection of DNX-2401	—	COMPLETED	2018-03-15	NCT02197169
Cavion, Inc.	Mibefradil with Radiation	—	COMPLETED	2017-09-29	NCT02202993
Boehringer Ingelheim	Temozolomide	Alkylating Drug [EPC]	COMPLETED	2017-09-12	NCT00977431
NuvOx LLC	NVX-108	—	COMPLETED	2017-08-31	NCT02189109
Sichuan J.Z. Bio-chemical Science and Technology Development Co., Ltd	Chlorogenic acid	—	COMPLETED	2017-08-23	NCT02728349
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.	Bevacizumab injection	—	COMPLETED	2017-08-18	NCT05476341
Vaximm GmbH	VXM01	—	COMPLETED	2017-08	NCT02718443
Istari Oncology, Inc.	Recombinant nonpathogenic polio-rhinovirus chimera (PVSRIPO)	—	COMPLETED	2017-06-27	NCT01491893
AbbVie	ABT-414	—	COMPLETED	2017-06-19	NCT01800695
Novartis	BKM120 + temozolomide	—	COMPLETED	2017-05-17	NCT01473901
Kartos Therapeutics, Inc.	AMG 232	—	COMPLETED	2017-03-15	NCT01723020
Precision Life Sciences Group	ICT-121 DC vaccine	—	COMPLETED	2017-03	NCT02049489
Tocagen Inc.	Toca 511 vector	—	COMPLETED	2016-08-18	NCT01156584
Novartis	buparlisib	—	COMPLETED	2016-07-07	NCT01934361
Tocagen Inc.	Toca 511 vector	—	COMPLETED	2016-04-12	NCT01470794
Amgen	AMG 595	—	COMPLETED	2016-04	NCT01475006
Tocagen Inc.	Toca 511	—	COMPLETED	2016-03-03	NCT01985256
Novartis	LDE225	—	COMPLETED	2015-04	NCT01576666
Roche	GDC-0084	—	COMPLETED	2015-01	NCT01547546
Roche	RO5323441 + bevacizumab [Avastin]	—	COMPLETED	2013-02	NCT01308684
CytoVac A/S	ALECSAT cell based immunotherapy	—	COMPLETED	2012-11	NCT01588769
Exelixis	XL184	—	COMPLETED	2012-11	NCT00960492
Sanofi	XL765 (SAR245409)	—	COMPLETED	2012-06	NCT01240460
Merck	MK-4827	—	COMPLETED	2012-04	NCT01294735
Sanofi	XL765 (SAR245409)	—	COMPLETED	2012-02	NCT00704080
Monteris Medical	—	—	COMPLETED	2009-10	NCT00747253
Taiho Oncology, Inc.	TAS2940	—	TERMINATED	2025-02-26	NCT04982926
Novartis	68Ga-FF58	—	TERMINATED	2024-12-13	NCT05977322
Biodexa Pharmaceuticals	MTX110	—	TERMINATED	2024-09-10	NCT05324501
Bristol-Myers Squibb	CC-90010	—	TERMINATED	2024-07-09	NCT04324840
Bristol-Myers Squibb	CC-90010	—	TERMINATED	2024-06-03	NCT04047303
OncoSynergy, Inc.	OS2966	—	TERMINATED	2023-02-27	NCT04608812
Samus Therapeutics, Inc.	Icapamespib	—	TERMINATED	2022-11-04	NCT04782609
Nuvation Bio Inc.	NUV-422	—	TERMINATED	2022-08-31	NCT04541225
Basilea Pharmaceutica	Microtubule-Targeted Agent BAL101553	—	TERMINATED	2022-06-03	NCT03250299
Vanquish Oncology, Inc.	PAC-1 Compound	—	TERMINATED	2021-12-31	NCT03332355
Celularity Incorporated	CYNK001-IV	—	TERMINATED	2021-08-10	NCT04489420
Amgen	AMG 596	—	TERMINATED	2021-07-01	NCT03296696
Tocagen Inc.	Toca 511 vector	—	TERMINATED	2019-12	NCT04327011
Monteris Medical	Radiation therapy and temozolomide	—	TERMINATED	2018-09-14	NCT02880410
AbbVie	ABBV-221	—	TERMINATED	2018-03-15	NCT02365662
Actelion	Macitentan in combination with RT and TMZ	—	TERMINATED	2016-09-29	NCT02254954
Actelion	Phase 1 Dose Escalation	—	TERMINATED	2016-01	NCT01499251
Immatics Biotechnologies GmbH	Cyclophosphamide	DNA	TERMINATED	2014-04	NCT01403285
Shanghai Simnova Biotechnology Co.,Ltd.	SNC109	—	ENROLLING BY INVITATION	2024-12-31	NCT06616727
Philogen S.p.A.	Onfekafusp alfa	—	WITHDRAWN	2024-12-31	NCT05304663
Pfizer	Crizotinib plus VEGF inhibitor combinations	—	WITHDRAWN	2013-11	NCT01441388
Millennium Pharmaceuticals, Inc.	Tandutinib, bevacizumab, and temozolomide	—	WITHDRAWN	2010-05	NCT00904852

Precision Medicine Biomarkers

All biomarkers →

Biomarkers used for patient selection in Glioblastoma

VEGF (17)

Novel Glioblastoma Drugs by Company (New molecular entities)

No novel drugs found for this indication.

Reformulations (3 drugs) Click to expand

Reformulations are FDA-approved versions of existing molecules in new dosage forms (e.g., oral solution vs tablet, extended-release vs immediate-release). They require a new NDA but use an already-proven active ingredient.

Glioblastoma Drug Targets

Molecular targets of approved and investigational Glioblastoma drugs — 4 targets tracked.

VEGFA 5 DNA 3 RNA 3 proteins 1

Biosimilars (6 BLA approved) Click to expand

Biosimilars are biological products highly similar to FDA-approved reference biologics with no clinically meaningful differences in safety, purity, or potency.

BIO-THERA SOLUTIONS LTD